The Effect of Analgesia Based Sedation Protocol on Brain Function of Critical Care Patients

NCT ID: NCT02078583

Last Updated: 2014-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Benzodiazepines is a commonly uesd sedative medication,there are many reports that Benzodiazepines is associated with delirium ,but using of analgesia reduces benzodiazepines requirements .The purpose of this study is to determine whether analgesia based sedation protocol reduces the incident of delirium.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Remifentanil,midazolam

Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation

Group Type EXPERIMENTAL

Remifentanil

Intervention Type DRUG

Fentanyl,midazolam

Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation

Group Type EXPERIMENTAL

Fentanyl

Intervention Type DRUG

Normal saline

Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation

Group Type PLACEBO_COMPARATOR

Normal saline

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fentanyl

Intervention Type DRUG

Remifentanil

Intervention Type DRUG

Normal saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signing a consent form
* postoperative patient
* Requirement for mechanical ventilation and anticipate time of mechanical ventilation more than 24 hours
* Requirement for sedation
* Age more than 18 and less than 85 years old

Exclusion Criteria

* Unstable blood circulation
* Heart rate less than 50 beats per minute
* II ° ~ III ° atrioventricular conduct block
* Intracranial lesions 、neurosurgical intervention and mental disability inability to cooperate;
* Receipt of antipsychotics 、hypnotic drugs before surgery ;
* Alcohol abuse;
* Liver failure class Child-Pugh C;
* Acute Respiratory Distress Syndrome;
* Acute or chronic renal failure;
* Other severe diseases ,septic shock;
* Receipt of neuromuscular blocking drug;
* Pregnancy and nursing woman;
* Allergy to investigational drug or other contraindication.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dan Liu, Resident physician

Role: CONTACT

+8613811365572

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEKING SEDATION

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dexmedetomidine for Continuous Sedation
NCT00226785 TERMINATED PHASE3